clinical research prime

Intranasal RSV

• 24-59 months of age
• A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine in RSV Seropositive Children.
• Participants will receive study related treatment at no cost and will be compensated for time and travel